Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00425386 · ClinicalTrials.gov registry record · Phase 2
Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
A Phase 2 study of Kidney Cancer, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT00425386 is a Phase 2 study of Kidney Cancer that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 60 participants, below the 879-participant average among 60 other Kidney Cancer trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT00425386, a Phase 2 study of Kidney Cancer, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
RATIONALE: Sunitinib and erlotinib may stop the growth of tumor cell by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying the best dose of erlotinib when given together with sunitinib and to see how well they work in treating patients with unresectable or metastatic kidney cancer.
Conditions Studied
Interventions
- PROCEDURE biopsy
- DRUG erlotinib hydrochloride
- DRUG sunitinib malate
Study Locations (4)
Oregon
- Providence Cancer Center at Providence Portland Medical Center - Portland
- OHSU Knight Cancer Institute - Portland
- Salem Hospital - Salem
California
- University of Southern California - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-08 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00425386
The ClinicalTrials.gov registry entry for NCT00425386 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 879-participant average among 60 other Kidney Cancer trials with a reported enrollment target (93% lower). The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 3 interventions - of which biopsy is the first listed.
NCT00425386 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Oregon, California.
Frequently Asked Questions
What is clinical trial NCT00425386 about?
NCT00425386 is a clinical study titled "Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer". RATIONALE: Sunitinib and erlotinib may stop the growth of tumor cell by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying the best dose of erlotini...
What is the current status of trial NCT00425386?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2006-08. Estimated completion is 2014-03.
What conditions does trial NCT00425386 study?
This clinical trial studies the following conditions: Kidney Cancer.
What interventions are being tested in trial NCT00425386?
The interventions under investigation include: biopsy (PROCEDURE), erlotinib hydrochloride (DRUG), sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT00425386?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00425386 being conducted?
This trial has 4 study locations across California, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
NSAID Use After Robotic Partial Nephrectomy
RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
RECRUITING · Phase 2
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.